FDA hiring wave
This article was originally published in The Tan Sheet
Executive SummaryWith additional congressional appropriations and user-fee dollars to spend, FDA is in the process of adding the most staff since the counterterrorism hiring initiative following the terrorist attacks of Sept. 11, 2001, an agency spokesperson says. The current influx comprises 1,317 new employees, including 444 new positions in the Center for Drug Evaluation and Research and 91 new positions in the Center for Food Safety and Applied Nutrition, which will give CFSAN a 10 percent increase in employment by the end of 2008, according to the spokesperson. So far, 850 new hires are scientific and medical professionals posted across the agency, including chemists, pharmacologists, consumer safety officers and general health scientists, the spokesperson says
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.